TC
TEVA icon

TAP Consulting’s Teva Pharmaceuticals TEVA Stock Holding History

TAP Consulting’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-186
Closed -$1K – 495
2021
Q4 		$1K Buy
+186
New +$1.68K ﹤0.01% 547

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

TAP Consulting's TEVA Position: Q1 2022 in Review

TAP Consulting sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 186 shares — an estimated $1K sold.

TAP Consulting first reported a position in TEVA in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • TAP Consulting reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • TAP Consulting sold 186 Teva Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • TAP Consulting first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • TAP Consulting's Teva Pharmaceuticals position peaked at $1K in Q4 2021.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.